39
Participants
Start Date
July 25, 2018
Primary Completion Date
January 31, 2021
Study Completion Date
June 30, 2021
Tomivosertib (eFT-508)
Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
Anne Arundel Medical Center, Annapolis
Virginia Cancer Specialists, PC, Fairfax
Spartanburg Medical Center, Spartanburg
Columbus Regional Research Institute, Columbus
Universty of Toledo Medical Center, Toledo
Gabrail Cancer Center, Canton
Indiana University Health Melvin & Bren Simon Cancer Center, Indianapolis
Karmanos Cancer Institute, Detroit
University of Wisconsin Clinical Science Center, Madison
Avera Cancer Institute, Sioux Falls
Oncology Consultants, Houston
Saint Alphonsus Regional Medical Center, Boise
University of Arizona - Cancer Center, Tucson
Hoag Memorial Hospital Presbyterian, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles
Pacific Shores Medical Group, Long Beach
St. Mary's Medical Center, San Francisco
St. Joseph Heritage Healthcare, Santa Rosa
Providence Portland Medical Center, Portland
Lead Sponsor
Effector Therapeutics
INDUSTRY